X-linked adrenal hypoplasia congenita (AHC) is a rare congenital disorder of primary adrenal insufficiency and hypogonadotropic hypogonadism (HH) in boys \[[@B1]\]. It is caused by loss-of-function mutations in dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1 (*DAX1*), which is a nuclear transcription factor that plays a critical role in human adrenal, pituitary, and gonadal development. DAX-1 is encoded by the *NR0B1* gene located on the chromosome Xp21 \[[@B1], [@B2]\], which has two exons that encode a 470-amino-acid protein. The mechanism of DAX-1 action remains unclear, but most studies indicate that DAX-1 acts as a transcriptional repressor of genes involved in the steroidogenic pathway and at all levels of the hypothalamic--pituitary--gonadal axis \[[@B5]\]. Loss-of-function of *DAX1* is associated with adrenal hypoplasia and reproductive dysfunction \[[@B1]\].

Most male subjects with *DAX1* mutations present with primary adrenal failure or salt-losing in infancy or early childhood and develop HH and azoospermia in adolescence. Nonclassic phenotypes, including late-onset Addison disease or transient precocious puberty, have been described in rare cases \[[@B9]\]. Patients with X-linked AHC can present with different phenotypes, and a genotype--phenotype correlation is not well established \[[@B3], [@B4]\]. More than 200 *DAX1* mutations have been described in different ethnic groups (<http://www.hgmd.org>) \[[@B16]\]. Most of these mutations are nonsense or frameshift mutations leading to premature truncation of the protein. Missense mutations are mainly clustered at the carboxyl terminus of the putative ligand-binding region of DAX-1 \[[@B4]\]. We describe seven patients with *DAX1* mutations presenting with unusual phenotypes. Three novel *DAX1* mutations and three known mutations were identified, and the activities of the mutants were characterized to explore genotype/phenotype correlations.

1. Patients and Methods {#s6}
=======================

A. Patients {#s7}
-----------

Five unrelated patients and two cousins with clinical and hormonal findings suggesting X-linked AHC were recruited from the Division of Pediatric Endocrinology, King Chulalongkorn Memorial Hospital from 2015 to 2017. This study was approved by the Institutional Review Board of Faculty of Medicine, Chulalongkorn University (COA no. 954/2016).

Patient I, the only child of nonconsanguineous parents, weighed 3.0 kg at birth and had normal male genitalia, with phallic length 3.5 cm and descended testes. The first symptoms were diarrhea and poor feeding at 1 month of age. At the local hospital, he was found to have salt-losing crisis and multiple seizure episodes due to hypoglycemia. Hydrocortisone was given, and the patient was referred to our hospital. The patient recovered slowly due to nosocomial pneumonia complication. He was discharged after 35 days. He was maintained with oral hydrocortisone 30 mg/m^2^/d and fludrocortisone 0.2 mg/d with the presumptive diagnosis of congenital adrenal hyperplasia. A 60-minute ACTH stimulation test was performed at age 3.5 months after the discontinuation of hydrocortisone for 36 h after weaning onto a lower daily dose (∼10 mg/m^2^/d) for 1 week. An ACTH test failed to increase serum levels of progesterone, 17-hydroxyprogesterone (17OHP), and cortisol \[at 60 min: 0.1 ng/mL (0.32 nmol/L), 0.34 ng/mL (1.03 nmol/L), and \<0.1 μg/dL (\<3 nmol/L), respectively\]. Hypogonadotropic hypogonadism was diagnosed at the age of 15 years, and testosterone therapy was started. The patient is now 20 years old with rather good physical health. He was diagnosed with well-controlled epilepsy and mild intellectual disability. He is on prednisolone 7.5 mg/d and fludrocortisone 0.15 mg/d. His penile length is 7 cm (Tanner stage V), and testicular volume is 4 mL bilaterally.

Patient II was the first cousin of patient I. He was born at term with a birth weight of 3.15 kg. His skin was noted to be severely dark at birth. At 2 days of age, he had drowsiness and was found to have hypoglycemia \[blood sugar 9 mg/dL (0.5 mmol/L)\]. At 6 days of age, electrolytes suggested salt-losing (Na 131, K 6.1, Cl 97, CO~2~ 19 mmol/L). An ACTH stimulation test confirmed primary adrenal insufficiency \[at 60 min: cortisol 1.1 μg/dL (30 nmol/L)\]. The patient recovered under treatment with hydrocortisone. Ultrasound of the abdomen could not identify either adrenal gland.

Patient III was born at term with a birth weight of 3.17 kg to nonconsanguineous parents. He had moderate birth asphyxia and was intubated at birth. He was admitted to the neonatal intensive care unit of a local hospital for 1 week before being discharged. The initial diagnosis was *Klebsiella* pneumonia with hypovolemic shock. At age 24 days, he had intractable seizure and was admitted to the neonatal intensive care unit again. In the second admission, his laboratory results showed that he had salt-losing crisis and hypoglycemia. Physical examination revealed severe hyperpigmentation. Intravenous hydrocortisone and NaCl were given, and he was referred to our hospital. Critical blood samples obtained when the patient had clinical signs of shock showed ACTH levels of 185 pg/mL (41 pmol/L), cortisol levels of 1.4 μg/dL (38.6 nmol/L), and 17OHP levels of 1.9 ng/mL (5.7 nmol/L). Adrenal ultrasound demonstrated very small glands bilaterally without evidence of mass lesion. His pedigree was highly suggestive of X-linked recessive transmission because nine boys in previous generations had unexplained death during infancy.

Patient IV was a 17-year-old boy who presented with progressive hyperpigmentation over the past 2 years. At the time of admission, it was noted that he had not yet developed secondary sexual characteristics. Physical examination revealed an obese eunuchoid-appearance boy with generalized hyperpigmentation. His genitalia were normal prepubertal male (Tanner stage I), and his testes were small at 4 mL in volume. His baseline LH (1.15 IU/L), FSH (4.04 IU/L), and testosterone (14 ng/dL, 0.5 nmol/L) were all prepubertal. Electrolytes were normal, and the patient denied a serious past medical history. His morning basal ACTH was 2910 pg/mL (640 pmol/L), cortisol was 2.2 μg/dL (60.7 nmol/L), and 17OHP was 0.08 ng/mL (0.24 nmol/L). CT of the abdomen showed bilateral adrenal glands hypoplasia. MRI of the pituitary revealed a small pituitary gland for age.

Patient V was a 1-month-old term newborn from nonconsanguineous parents. Patient V presented with poor feeding, diarrhea, and lethargy for 8 days. Physical examination revealed poor weight gain, hypotension, severe dehydration, marked hyperpigmentation, and normal male genitalia (penile length 4 cm) with descended testes. Electrolytes documented salt-wasting (Na 109, K 9.9, Cl 82, CO~2~ 13.6 mmol/L). Basal cortisol levels were normal (8.4 μg/dL, 232 nmol/L), but there was poor cortisol response to ACTH stimulation \[10.9 μg/dL (301 nmol/L) at 60 min\]. 17OHP was not hyper-responsive to ACTH \[475 ng/dL (14.4 nmol/L) at 0 min, 716 ng/dL (21.7 nmol/L) at 60 min\], whereas androstenedione (1.61 ng/mL, 5.6 nmol/L) and testosterone (243 ng/dL, 8.4 nmol/L) were normal. He was diagnosed with atypical congenital adrenal hyperplasia and was treated with oral hydrocortisone 12.5 mg/m^2^/d and remained well, with normal electrolytes and suppressed 17OHP levels. At the age of 10 months, he developed acne and rapid penile enlargement (penile length 8.5 cm, testes 3 mL bilaterally) without bone age advancement. Luteinizing hormone--releasing hormone stimulation test (Relisorm,® 100 µg IV, Serono, CA) demonstrated a GnRH-independent precocious puberty (basal LH 0.6, peak LH 7.5 IU/L by radioimmunoassay), with low baseline androstenedione (1.61 ng/mL, 5.6 nmol/L) and DHEAS (0.26 μg/mL, 706 nmol/L) but high testosterone levels (320 ng/dL, 11.1 nmol/L). MRI of the pituitary was normal, and MRI of the abdomen showed small adrenals. After increasing the hydrocortisone dose, the patient's acne and genital development ceased, and testosterone decreased (30 ng/dL, 1.04 nmol/L). During follow-up, it appeared that acne, rapid growth, and elevated testosterone levels would recur when the hydrocortisone dose was inadequate. A repeated ACTH test (after 5 days hydrocortisone suspension) at 11 years of age showed very low stimulated cortisol and all steroidogenic precursors suggesting AHC.

Patient VI was first evaluated at 3.5 years of age due to progressive hyperpigmentation and symptoms of salt-losing (nausea, vomiting, and diarrhea). His electrolytes confirmed salt-losing. His baseline ACTH was 254 pg/mL (56 pmol/L), and he had undetectable cortisol levels. His aldosterone levels were 2 pg/mL (0.006 nmol/L) (normal, 10 to 160 pg/mL), and plasma renin activity was 9.6 ng/mL/h (2.7 ng/L/s) (normal, 0.2 to 2.8 ng/mL/h). An ACTH stimulation test failed to increase cortisol \[0.04 μg/dL (1.1 nmol/L) at 60 minutes\]. CT scan revealed no visible bilateral adrenal glands. He was given hydrocortisone and fludrocortisone replacement and remained well. At age 13 years, his pubertal development was assessed to be Tanner I (testicular volume 2 mL bilaterally). His laboratory results showed FSH of 1.5 IU/L, LH \<0.1 IU/L, and testosterone \<3 ng/dL (\<0.1 nmol/L). A pituitary MRI was unremarkable. At age 14 years, he was commenced on hCG therapy for pubertal induction.

Patient VII was a 12-year-old boy referred to our endocrine service with a diagnosis of congenital adrenal insufficiency and severe short stature. The patient was born at term with a normal birth weight (2.7 kg). In the first month of life, he had salt-wasting syndrome and multiple seizure episodes due to hypoglycemia. He was diagnosed with adrenal insufficiency and received hydrocortisone replacement at a local community hospital. The mean daily glucocorticoid dose was ∼11 to 14 mg/m^2^/d. At age 12 years, he was referred for further evaluation of severe short stature (height, 112 cm; weight, 35 kg; bone age, 7 years). GH provocative tests were performed with estrogen priming, and complete GH deficiency was confirmed (peak GH 0.8 ng/mL, 0.8 μg/L). Pituitary MRI was normal. His free thyroxine was low normal (0.9 ng/dL; normal, 0.8 to 1.8 ng/dL; 11.6 pmol/L) with slightly high TSH (4.5 mU/L; normal, 0.3 to 4.1 mU/L), so [l]{.smallcaps}-thyroxine treatment was given at 50 μg/d. A thyrotropin-releasing hormone stimulation test was not performed due to unavailability of medication. An ACTH test proved primary adrenal insufficiency with baseline ACTH 1128 pg/mL (248 pmol/L), and peak cortisol at 60 minutes was undetectable at \<1 μg/dL (\<28 nmol/L). At age 13 years, he had no signs of puberty with small testes (1 mL bilaterally). His LH was \<0.1 IU/L, FSH was 0.2 IU/L, and testosterone was \<2.5 ng/dL (\<0.1 nmol/L). Growth hormone therapy was started with a good clinical response, but sex steroid therapy was delayed to maximize final height outcome.

B. DNA Sequencing and Mutation Analysis {#s8}
---------------------------------------

With informed consent, leukocyte genomic DNA was extracted using QIAamp^®^ DNA Blood Mini Kit (Qiagen, Germantown, MD) according to the manufacturer's instructions. The two exons of *DAX1 (NR0B1)* were amplified by PCR using specific oligonucleotide primer pairs designed by Primer3 program (<http://bioinfo.ut.ee/primer3-0.4.0/>). The PCR products were treated with Exonuclease I (ExoSAP-IT; USB Corporation, Cleveland, OH) and sent for direct sequencing at Macrogen Inc. (Seoul, Korea). The sequencing results were analyzed by Sequencher 4.2 (Gene Codes Corporation, Ann Arbor, MI) and compared with the published *DAX1* sequence (accession no.: NM_000475) \[[@B1]\].

C. Functional Analysis of Novel DAX1 Mutations {#s9}
----------------------------------------------

### C-1. Generation of expression vectors {#s10}

Commercial human pcDNA3.1-*DAX1*, pcDNA3.1-*SF1*, and pGL4.10-*StAR* promoter cDNA clones were obtained (OriGene, Rockville, MD) \[[@B17]\]. StAR promoter sequences (+3 to −1222) from human genomic DNA were cloned into pGL4.10 (Promega, Madison, WI), encoding the luciferase reporter gene luc2 using pfu DNA polymerase (Stratagene, La Jolla, CA). All mutant *DAX1* expression vectors were created using a QuickChange^®^ Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. The mutagenized and WT plasmids were separately transformed into bacterial cells by heat shock transformation. The transformed colonies were selected, and the plasmids were extracted by High-Speed Plasmid Mini Kit (Geneaid, Taiwan). The accuracy of the constructions was confirmed by direct sequencing.

### C-2. Transient transfection and luciferase assay {#s11}

Human embryonic kidney 293T cells (HEK293T) cells were cultured in DMEM containing 10% fetal bovine serum and antibiotics in T75 flasks at 37°C in 5% CO~2~ atmosphere. HEK293T cells were seeded into 12-well plates for transient transfection using X-tremeGENE9 DNA transfection reagent (Sigma-Aldrich, Singapore) according to the manufacturer's instructions. HEK293T cells were transiently cotransfected with 100 ng WT or mutant *DAX1* vector or empty vector with 100 ng *SF1* vector, 100 ng *StAR* promoter reporter, and 100 ng *Renilla* luciferase reporter plasmids (Promega, Madison, WI). Gene expression was determined 48 hours later using the Dual-Luciferase Reporter Assay System (Promega) with a luminometer (SpectraMax Microplate Reader; Molecular Devices, San Jose, CA). The luciferase activities were reported as a percentage of the empty vector control. The results were presented as mean ± SEM from three independent experiments, each performed in triplicate.

3. Results {#s12}
==========

A. DAX1 Mutation Analysis {#s13}
-------------------------

Direct DNA sequencing identified *DAX1* mutations in all patients. The clinical features and mutational results of all seven patients are summarized in [Table 1](#T1){ref-type="table"}. Patients I and II (cousins) carried a previously described in-frame single codon deletion c.805_807delGTC \[[@B2]\]. Patient III had known frame-shift mutation c.1148_1149delGG, which was previously described in a Thai boy with adrenal failure at 4 years of age \[[@B18]\]. Patients V and VI harbored novel frame-shift mutations, including c.363delG, and c.1062delC in exon 1, respectively (NCBI c.DNA reference sequence: NM_000475.4). These deletion mutations produce premature stop codons and truncated proteins. Patient IV had the novel missense mutation c.1156C\>T changing leucine 386 to phenylalanine (p.Leu386Phe). p.Leu386 is a highly conserved amino acid in the putative ligand binding domain. *In silico* analysis by SIFT (<http://www.blocks.fhcrc.org/sift>) and Polyphen (<http://www.genetics.bwh.harvard.edu/>) predicted p.Leu386Phe to be damaging and probably damaging, respectively. Patient VII had the insertion mutation c.501_502insG, which was previously described in a Spanish boy with complete adrenal failure in the neonatal period, hypogonadotropic hypogonadism, and severe short stature \[[@B19]\]. None of three novel mutations (c.363delG, c.1062delC, and c.1156C\>T) were detected in our 1024 ethnic-matched in-house whole exome sequencing database.

###### 

Clinical Features and Molecular Data of Patients With AHC

  Patient No.   Sex   Age of Onset   Clinical Features   Genotypes   Unusual Phenotypes                                                     
  ------------- ----- -------------- ------------------- ----------- -------------------- ----- ------------------ ------------------------ ---------------------------
  I             M     1 mo           X                   X           X                    X     c.805_807delGTC    p.Val269del              ---
  II            M     2 d            X                   X           X                    N/A   c.805_807delGTC    p.Val269del              ---
  III           M     24 d           X                   X           X                    N/A   c.1148_1149delGG   p.Gly383Aspfs\*5         ---
  IV            M     17 y           X                   **-**       ---                  X     **c.1156C\>T**     **p.Leu386Phe**          Late-onset Addison
  V             M     1 mo           X                   ---         X                    N/A   **c.363delG**      **p.Gly122Valfs\*142**   Precocious puberty
  VI            M     3.5 y          X                   ---         X                    X     **c.1062delC**     **p.Ala355Profs\*17**    ---
  VII           M     3 d            X                   X           X                    X     c.501_502insG      p.Ala170Argfs\*15        Growth hormone deficiency

Novel mutations are indicated in bold.

Abbreviations: H, hypoglycemia; HH, hypogonadotropic hypogonadism; N/A, not applicable; P, hyperpigmentation; SW, salt-wasting.

B. Gene Expression Studies {#s14}
--------------------------

DAX-1 and SF-1 proteins interact on the promoter of the *StAR* gene \[[@B20]\]. DAX-1 acts as a powerful transcriptional repressor of *StAR* gene expression, whereas SF-1 acts as a transcriptional activator \[[@B7]\]. Therefore, we cotransfected HEK293T cells with a luciferase reporter construct containing the human *StAR* promoter region with expression constructs containing human full-length cDNAs for *SF1* and *DAX1* (WT or mutants) to investigate whether our patients' mutations would impair the repressor function of DAX-1. WT DAX-1 suppressed basal transcription activity of the pcDNA3.1 vector down to 9%. This suppression was markedly reduced with each of the DAX-1 mutant vectors tested (p.Val269del, 174%; p.Gly383Aspfs\*5, 115%; p.Ala170Argfs\*15, 92%; p.Ala355Profs\*17, 46%; p.Gly122Valfs\*142, 67%; p.Leu386Phe, 76%) ([Fig. 1](#F1){ref-type="fig"}). The respective repressor activities of p.Ala170Argfs\*15, p.Ala355Profs\*17, p.Gly122Valfs\*142, and p.Leu386Phe were ∼9%, 59%, 36%, and 26% of WT activity, whereas p.Val269del and p.Gly383Aspfs\*5 mutants led to increase *StAR* transcriptional activities by 74%, and 15% of the basal transcription activity of the empty vector. All of the mutant DAX-1 proteins exhibited significantly less repressive activity than WT (*P* \< 0.05). These results confirm that the DAX-1 mutants displayed loss of *trans*-repression of *StAR* transcriptional activities.

![Functional effects of DAX-1 mutants. The effects of WT DAX-1 and its mutants on basal transcriptional activity were studied in dual-luciferase assays. WT DAX-1 greatly repressed on basal transcription activities of the pcDNA3.1 vector. Mutant DAX-1 expression vectors (p.Val269del, p.Gly383Aspfs\*5, p.Leu386Phe, p.Gly122Valfs\*142, p.Ala355Profs\*17, p.Ala170Argfs\*15) showed loss of repressor SF-1 activities on the promoter of the *StAR* gene. Relative luciferase activities are expressed as the mean ± SEM for three independent experiments, each performed in triplicate. \*Significant differences of luciferase activities between the mutants and WT (*P* \< 0.05).](js.2018-00270f1){#F1}

4. Discussion {#s15}
=============

X-linked AHC is caused by mutations in DAX-1, encoded by the *NR0B1* gene. DAX-1 is a nonliganded member of the nuclear hormone receptor superfamily that acts as a transcriptional repressor of genes involved in the steroidogenic pathway \[[@B21], [@B22]\]. We describe seven patients with X-linked AHC with four novel *DAX1* mutations and two previously reported mutations. Our findings confirm a broad, heterogeneous spectrum of phenotypes associated with *DAX1* mutations. Six patients had classic phenotypes with complete adrenal failure in infancy or early childhood. One patient (patient IV) presented with late-onset Addison disease during adolescence. Two patients had atypical clinical characteristics including GnRH-independent precocious puberty (patient V) and severe growth hormone deficiency (patient VII). Our results indicate that genotype--phenotype correlations within families (patients I and II) are likely. In addition, patient VII, who had a known frameshift mutation, had a clinical phenotype similar to a previously reported Spanish boy who presented with early-onset adrenal failure with complete growth hormone deficiency \[[@B19]\]. However, some *DAX1* mutations do not have good genotype--phenotype correlations \[[@B23]\], possibly due to other modifying genes, epigenetic, and nongenetic factors \[[@B24]\].

The DAX-1 protein consists of a DNA-binding domain and a putative ligand-binding domain (LBD). The DNA-binding domain, located at the amino terminus, contains repeating hydrophobic LXXLL motifs, which are essential for their interaction with nuclear receptors and protein--protein interactions. The putative LBD at the carboxyl terminus acts as a molecular switch by changing its conformation to convert the receptor from a transcriptional repressor to activator \[[@B5], [@B6]\].

At least 200 different mutations in *DAX1* have been described, including nonsense, frameshifts, and point (missense) mutations. Nonsense and frameshift mutations are found throughout the gene/protein and are usually associated with a severe phenotype \[[@B4]\]. By contrast, missense mutations are clustered in the LBD with several hotspots, suggesting this domain is functionally essential \[[@B4]\]. Some specific changes in these regions have been associated with a late-onset phenotype \[[@B9], [@B14], [@B15]\]. Contiguous gene deletions account for approximately one-third of published cases \[[@B25]\].

We identified six *DAX1* mutations, of which two are novel frame-shift mutations \[c.363delG (p.Gly122Valfs\*142), c.1062delC (p.Ala355Profs\*17)\], one is novel missense mutation (p.Leu386Phe), and three are the known mutations \[c.1148_1149delGG (p.Gly383Aspfs\*5), c.805_807delGTC (p.Val269del), and c.501_502insG (p.Ala170Argfs\*15)\] ([Fig. 2](#F2){ref-type="fig"}). All these *DAX1* mutations led to loss of repression of *StAR* transcriptional activities *in vitro* ([Fig. 1](#F1){ref-type="fig"}). However, the manifestations and severity of disease differed substantially among our patients. Patients I and II, who had classic, severe phenotypes, had the in-frame single codon deletion \[c.805_807delGTC (p.Val269del)\], which severely impaired transcriptional repression of StAR in our *in vitro* assays. Patients III, V, and VII also had severe disease and carried frame-shift mutations that severely reduced activities. Patient IV had a milder phenotype presenting with progressive pigmentation and hypogonadotropic hypogonadism at age 17 years and carried the novel p.Leu386Phe mutation. To our knowledge, only 10 previously reported cases presented with late-onset Addison disease manifesting in adolescence or adulthood \[[@B9]\]. Most missense mutations in *DAX1* are reported in the putative carboxyl terminal LBD, especially between codons 262 to 300 and 361 to 385 \[[@B4]\]. The mutations associated with late-onset phenotypes include p.Q37X, p.W39X, p.S259P, p.P279L, p.Gln305Hisfs\*67 (c.915delG), p.Y380D, and p.I439S \[[@B9]\]. Some of these mutations were tested *in vitro* and retained partial function in different gene transcription assays \[[@B11], [@B14], [@B15], [@B26]\]. Our patient added to previously described cases of late-onset AHC and expands the genotypic spectrum of *DAX1* mutations that can present with a milder or late-onset phenotype. p.Leu386Phe retained partial function in luciferase transcription assays. Leu386 is a highly conserved residue that is conserved among fish, chicken, frogs, and mammals. The crystal structure of DAX-1 bound to its target nuclear receptor LRH-1 \[[@B6]\] shows that Leu386 is in the hydrophobic core of the protein. We hypothesize that the bulkier phenylalanine residue interferes with a function of the conserved leucine. Thus, substitution of Phe for Leu may affect protein complex interactions or nuclear localization.

![Schematic representation of the position of all identified *DAX1* mutations in this study.](js.2018-00270f2){#F2}

The majority of *DAX1* mutations with adult-onset AHC also had HH; therefore, late-onset Addison disease with HH or infertility should prompt genetic testing of *DAX1*. However, *DAX1* mutations appear to be rare in men with only infertility or adult-onset Addison \[[@B25], [@B27]\]. Patient V, who carried p.Gly122Valfs\*142 (c.363delG), presented with early-onset AHC but developed signs of puberty (acne, penile enlargement) at 10 months of age. The luteinizing hormone--releasing hormone stimulation test demonstrated GnRH-independent sexual precocity with high testosterone levels. After starting hydrocortisone treatment, acne and penile enlargement were reversed and testosterone levels were normalized, indicating ACTH-dependent sexual precocity. Sexual precocity in early childhood is a rare and atypical presentation of *DAX1* mutations \[[@B28]\]. A Brazilian boy with X-linked AHC had pubic hair and enlarged penis at age 2 years \[[@B28]\], and a 9-month-old boy had classic AHC and early sexual development \[[@B29]\]. The GnRH test indicated gonadotropin-independent sexual precocity in both cases. In contrast, two previous studies \[[@B30], [@B31]\] described mild testicular enlargement in boys with *DAX1* mutations who were stable on steroid replacement. In these cases, there was no evidence of true central precocious puberty with a prepubertal GnRH test. Although the exact mechanism of this condition is still unclear, the authors postulated that high ACTH might stimulate testicular steroidogenesis via melanocortin receptor type 1 and autonomous Leydig cell hyperplasia in testes, which could induce sexual precocity in boys with AHC \[[@B28]\]. However, further studies are needed to confirm these hypotheses.

Patient VII carried the frameshift mutation c.501_502insG (p.Ala170Argfs\*15), which was described previously in a Spanish boy with complete neonatal adrenal failure, HH, and short stature without identified cause \[[@B19]\]. Patient VII had early-onset adrenal failure and very poor linear growth; hormonal tests identified complete growth hormone deficiency and possible central hypothyroidism. Short stature with growth hormone deficiency has been reported in a few children with *DAX1* mutations \[[@B8], [@B32], [@B33]\]. This is a potentially new clinical finding of AHC. The mechanism of growth hormone deficiency in patients with AHC is unknown. DAX-1 plays a key role in the development of the adrenal gland and in pituitary development. DAX-1 is expressed in embryonic stem cells, steroidogenic tissues (gonads, adrenals), the ventromedial hypothalamus, and the pituitary early in development \[[@B5], [@B34]\]. Thus, it might affect differentiation of pituitary cells other than gonadotrophs. Our case and others highlight that defects in DAX-1 could result in rare pituitary hormone deficits, but the mechanisms by which pituitary somatotropes or thyrotropes respond to DAX-1 remain unknown. The identification of more patients with *DAX1* mutations who have selective or combined hypopituitarism will be most informative.
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:   17-hydroxyprogesterone
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:   adrenal hypoplasia congenita
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:   dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1
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